- FDA approves Jubilant Life Sciences' quetiapine fumarate tablets
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA approves Takeda's Brintellix for depression
- FDA approves Bayer's Nexavar for thyroid cancer
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
TOKYO — The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.
Otsuka Pharmaceutical and H. Lundbeck announced the FDA approval of Abilify Maintena (aripiprazole) for extended-release injectable suspension, an intramuscular depot formulation indicated for the treatment of schizophrenia.
The companies described Abilify Maintena as the first dopamine D2 partial agonist approved as a once-monthly injection, contributing to a new treatment option to address the ongoing need for relapse prevention in patients with schizophrenia.